Skip to main content
SpringerLink
Log in

Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

This study aims to investigate the apoptotic and anti-angiogenic effect of Zoledronic acid on hormone-refractory prostate cancer cell lines. XTT cell proliferation assay used to assess cytotoxicity. Caspase 3/7 activity and DNA fragmentation were measured to verify apoptosis. Angiogenic cytokine profiles investigated using the human angiogenesis antibody array I. Administration of Zoledronic acid on PC-3 and DU-145 prostate cancer cell lines resulted in increased cytotoxicity and apoptosis with a time- and dose-related manner. Also, the administration of Zoledronic acid significantly reduced several angiogenic cytokine productions in PC-3 and DU-145 cell lines. Zoledronic acid successfully induced apoptosis and reduced various angiogenic cytokine production in hormone-refractory prostate cancer cell lines. Novel treatment protocols may be developed in the future with chemotherapeutic combinations for the treatment of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brausi M, Hoskin P, Andritsch E, Banks I, Beishon M, Boyle H, Colecchia M, Delgado-Bolton R, Hockel M, Leonard K, Lovey J, Maroto P, Mastris K, Medeiros R, Naredi P, Oyen R, de Reijke T, Selby P, Saarto T, Valdagni R, Costa A, Poortmans P (2020) ECCO essential requirements for quality cancer care: prostate cancer. Crit Rev Oncol Hematol 148:102861. https://doi.org/10.1016/j.critrevonc.2019.102861

    Article  PubMed  Google Scholar 

  2. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003

    Article  PubMed  Google Scholar 

  3. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642. https://doi.org/10.1016/j.eururo.2016.08.002

    Article  PubMed  Google Scholar 

  4. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74(2):210–216. https://doi.org/10.1002/pros.22742

    Article  PubMed  Google Scholar 

  5. Karaca B, Kucukzeybek Y, Gorumlu G, Erten C, Gul MK, Cengiz E, Atmaca H, Uzunoglu S, Sanli UA, Karabulut B, Uslu R (2008) Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. Eur Cytokine Netw 19(4):176–184. https://doi.org/10.1684/ecn.2008.0139

    Article  CAS  PubMed  Google Scholar 

  6. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21(3):274–281. https://doi.org/10.1002/ijc.2910210305

    Article  CAS  PubMed  Google Scholar 

  7. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17(1):16–23

    CAS  PubMed  Google Scholar 

  8. Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli UA, Baran Y, Uslu R (2009) Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 33(2):239–246. https://doi.org/10.1016/j.cellbi.2008.11.011

    Article  CAS  PubMed  Google Scholar 

  9. Karabulut B, Karaca B, Atmaca H, Kisim A, Uzunoglu S, Sezgin C, Uslu R (2011) Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines. Mol Biol Rep 38(1):249–259. https://doi.org/10.1007/s11033-010-0102-6

    Article  CAS  PubMed  Google Scholar 

  10. Mani J, Vallo S, Barth K, Makarevic J, Juengel E, Bartsch G, Wiesner C, Haferkamp A, Blaheta RA (2012) Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer Prostat Dis 15(3):250–255. https://doi.org/10.1038/pcan.2012.9

    Article  CAS  Google Scholar 

  11. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL (1985) Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24(20):5480–5486. https://doi.org/10.1021/bi00341a030

    Article  CAS  PubMed  Google Scholar 

  12. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF (2006) A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 103(39):14519–14524. https://doi.org/10.1073/pnas.0606708103

    Article  CAS  PubMed  Google Scholar 

  13. De Miguel P, Royuela BR, Ruiz A, Fraile B, Paniagua R (1999) Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11(9):722–727. https://doi.org/10.1006/cyto.1998.0443

    Article  PubMed  Google Scholar 

  14. Uysal-Onganer P, Djamgoz MB (2007) Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel. Mol Cancer 6:76. https://doi.org/10.1186/1476-4598-6-76

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig Z (2009) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16(1):155–169. https://doi.org/10.1677/ERC-08-0174

    Article  CAS  PubMed  Google Scholar 

  16. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET (2006) Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 66(6):3087–3095. https://doi.org/10.1158/0008-5472.CAN-05-3447

    Article  CAS  PubMed  Google Scholar 

  17. Asbagh LA, Uzunoglu S, Cal C (2008) Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines. Int Braz J Urol 34(3):355–363. https://doi.org/10.1590/s1677-55382008000300013. (discussion 364)

    Article  PubMed  Google Scholar 

  18. Yoshidome H, Kohno H, Shida T, Kimura F, Shimizu H, Ohtsuka M, Nakatani Y, Miyazaki M (2009) Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. Int J Oncol 34(4):923–930. https://doi.org/10.3892/ijo_00000218

    Article  CAS  PubMed  Google Scholar 

  19. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K, Heldin CH (1992) Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7(4):261–266. https://doi.org/10.3109/08977199209046408

    Article  CAS  PubMed  Google Scholar 

  20. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM (1998) Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 102(3):465–472. https://doi.org/10.1172/JCI3145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, Yasui W, Ohmoto Y, Kajiyama G, Fidler IJ, Tahara E (1998) Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 152(1):93–100

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN, Richmond A (1997) Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 62(5):588–597. https://doi.org/10.1002/jlb.62.5.588

    Article  CAS  PubMed  Google Scholar 

  23. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM (1999) Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 154(5):1503–1512. https://doi.org/10.1016/S0002-9440(10)65404-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nicholson B, Schaefer G, Theodorescu D (2001) Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev 20(3–4):297–319. https://doi.org/10.1023/a:1015543713485

    Article  CAS  PubMed  Google Scholar 

  25. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW, Cancer, Leukemia Group B (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7(7):1932–1936

    CAS  PubMed  Google Scholar 

  26. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165–176. https://doi.org/10.1053/ctrv.2000.0210

    Article  CAS  PubMed  Google Scholar 

  27. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82(8):1459–1468. https://doi.org/10.1054/bjoc.1999.1131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14(12):2048–2056. https://doi.org/10.1359/jbmr.1999.14.12.2048

    Article  CAS  PubMed  Google Scholar 

  29. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302(3):1055–1061. https://doi.org/10.1124/jpet.102.035295

    Article  CAS  PubMed  Google Scholar 

  30. Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114(5):623–633. https://doi.org/10.1172/JCI22087

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzi V, Gasparro S, Rocci L, Tonini G (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25(3):144–151. https://doi.org/10.1089/jir.2005.25.144

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Ege University, Kazim Dirik Mah, 35100, Izmir, Turkey

    Cenk Gokalp

Authors
  1. Cenk Gokalp
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CG literature search, collecting data, writing and editing the manuscript (internist, resident).

Corresponding author

Correspondence to Cenk Gokalp.

Ethics declarations

Conflict of interest

All the authors declared that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gokalp, C. Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines. Mol Biol Rep 47, 7675–7683 (2020). https://doi.org/10.1007/s11033-020-05840-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-020-05840-6

Keywords

Search

Navigation